PGGM Investments trimmed its position in Johnson & Johnson (NYSE:JNJ) by 39.1% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,727,200 shares of the company’s stock after selling 1,107,647 shares during the period. Johnson & Johnson accounts for 1.4% of PGGM Investments’ portfolio, making the stock its 12th biggest position. PGGM Investments owned approximately 0.06% of Johnson & Johnson worth $241,324,000 at the end of the most recent quarter.
Other hedge funds have also recently modified their holdings of the company. Harding Loevner LP purchased a new stake in Johnson & Johnson in the second quarter worth $106,000. Mountain Capital Investment Advisors Inc purchased a new stake in Johnson & Johnson in the second quarter worth $124,000. Cerebellum GP LLC purchased a new stake in Johnson & Johnson in the fourth quarter worth $166,000. Lenox Wealth Management Inc. grew its stake in shares of Johnson & Johnson by 1.7% in the second quarter. Lenox Wealth Management Inc. now owns 1,457 shares of the company’s stock worth $193,000 after acquiring an additional 24 shares during the last quarter. Finally, Jentner Corp purchased a new stake in shares of Johnson & Johnson in the fourth quarter worth $209,000. 67.18% of the stock is currently owned by institutional investors.
In other news, VP Paulus Stoffels sold 155,342 shares of the company’s stock in a transaction on Thursday, February 15th. The stock was sold at an average price of $129.86, for a total transaction of $20,172,712.12. Following the transaction, the vice president now directly owns 357,906 shares of the company’s stock, valued at $46,477,673.16. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Corporate insiders own 0.22% of the company’s stock.
Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Tuesday, April 17th. The company reported $2.06 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.00 by $0.06. The firm had revenue of $20.01 billion for the quarter, compared to the consensus estimate of $19.50 billion. Johnson & Johnson had a return on equity of 30.05% and a net margin of 1.58%. The company’s quarterly revenue was up 12.6% on a year-over-year basis. During the same period in the prior year, the company posted $1.83 earnings per share. research analysts predict that Johnson & Johnson will post 8.13 earnings per share for the current fiscal year.
JNJ has been the topic of a number of recent research reports. BTIG Research reissued a “sell” rating and issued a $110.00 target price on shares of Johnson & Johnson in a research note on Wednesday, January 24th. Vetr cut Johnson & Johnson from a “buy” rating to a “hold” rating and set a $147.40 target price on the stock. in a research note on Monday, January 8th. Credit Suisse Group set a $154.00 target price on Johnson & Johnson and gave the stock a “hold” rating in a research note on Monday, January 22nd. TheStreet cut Johnson & Johnson from an “a” rating to a “c+” rating in a research note on Monday, March 26th. Finally, Wells Fargo reissued an “outperform” rating and issued a $160.00 target price (up from $155.00) on shares of Johnson & Johnson in a research note on Friday, January 12th. Five research analysts have rated the stock with a sell rating, eight have assigned a hold rating and ten have assigned a buy rating to the stock. The company has an average rating of “Hold” and a consensus target price of $142.23.
ILLEGAL ACTIVITY NOTICE: This news story was posted by StockNewsTimes and is the sole property of of StockNewsTimes. If you are reading this news story on another publication, it was illegally copied and reposted in violation of U.S. and international copyright and trademark law. The legal version of this news story can be read at https://stocknewstimes.com/2018/04/25/pggm-investments-sells-1107647-shares-of-johnson-johnson-jnj.html.
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.